Table 1 Clinical characteristics of breast cancer patients
From: miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells
Patient demographics | ER+ | ER- | P-value |
|---|---|---|---|
Patients, n (%) | 26 (55.32%) | 21 (44.68%) | Â |
Mean age ± SD (years) | 53.44 ± 13.79 | 54.95 ± 10.13 | 0.68a |
Tumor stage, n (%) | Â | Â | Â |
   Stage I | 11 (42.31%) | 8 (38.10%) | 0.7699b |
   Stages II and III | 15 (57.69%) | 13 (61.90%) |  |
Tumor type, n (%) | Â | Â | Â |
   HER2+ | 15 (57.69%) | 12 (57.14%) | 0.9698b |
   HER2- | 11 (42.31%) | 9 (42.86%) |  |
5-year disease-free survival, n (%) | 16 (61.54%) | 13 (61.90%) | 0.9795b |